Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (May 2023)
28 slides from Matinas Biopharma's investor presentation, May 10, 2023
Slide 1: Corporate Presentation
MATINAS BIOPHARMA Corporate Presentation May 10, 2023 www.matinasbiopharma.com NYSE American: MTNB
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Matinas Has Developed Two Distinct Platforms for Delivering Therapeutic Cargo
Matinas Has Developed Two Distinct Platforms for Delivering Therapeutic Cargo Phosphatidylserine and its Unique Properties Link Both Platforms oe Cargo Routes of “Se Administration BB Characteristics 5$- Components ty Cellular uptake (in vitro) © In vivo delivery / efficacy Lipid Nanocrystals™ (LNCs
Slide 4: Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform
Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Delivery of small molecules and small oligonuceotides hte. fe3 G 3 » Successful delivery of small molecules, proteins, nucleic acid polymers (siRNA, ASOs), and vaccines Extra-hepatic targeting * Selective uptake driven
Slide 5: Phosphatidylserine Nanoparticles (PS-NPs): A New Delivery Option for mRNA
Phosphatidylserine Nanoparticles (PS-NPs) : A New Delivery Option for mRNA ‘Aqueous MRNA) — Lipid (+) Interior Specific Challenges with mRNA + Large size * Complex structure + Negative charge c ha PS iposomes cergocaring topless + Fragility in biological systems ae + Targeting Kintsine + Safely deli
Slide 6: Platforms are Clearly Differentiated from LNPs
Platforms are Clearly Differentiated from LNPs LNCs LNPs PS-NPs Small molecules Small oligos ° Cargo small oigos Large oligos raw olen Routes of cee ee Multiple (including oral) systemic systemic Administration PS-driven Injured/infected tissues Specific Delivery |p ecsional Phage, Primarily iver a
Slide 7: Phosphatidylserine Enables Cellular Targeting and Facilitates Intracellular Delivery
Phosphatidylserine Enables Cellular Targeting and Facilitates Intracellular Delivery Targeting Stressed Cells Externalize PS Normally, PS With injury, is confined to PS moves from the inner the inner layer layer to the outer layer (facing cytosol) of the cell membrane ‘CELL MEMBRANE PHOSPHATIDYLSERI
Slide 8: Internal and External Pipelines Extend Applications of LNCs and PS-NPs
Internal and External Pipelines Extend Applications of LNCs and PS-NPs Meteo te Rsk ap LNC-Fab fragment Internal platform programs (small oligos with LNCs) Undisclosed Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Collaborators MAT2203 Asperilus/IFL Phase 3 Ready LNC-Amphotericin
Slide 9: MAT2203: Oral Amphotericin B
MAT2203 Oral Amphotericin B Validating LNC Delivery with Small Molecules ‘BIOPHARMA
Slide 10: Addressing Emerging Threats From Fungal Infections
Addressing Emerging Threats From Fungal Infections 0 The World Health Organization (WHO) Matinas is leveraging the safety and efficacy of MAT2203 to meet released its first fungal priority the needs of both critical and high priority groups identified by WHO pathogens list to guide research and deve
Slide 11: MAT2203: A Novel Approach to Developing the Ideal Antifungal Agent
MAT2203: A Novel Approach to Developing the Ideal Antifungal Agent + Innate Amphotericin B IV Amphotericin B Characteristics Limitations © POTENT - Only available through broad-spectrum fungicidal IV administration © © © Minimal drug-drug interactions Low propensity for resistance Active against sus
Slide 12: Value Proposition for MAT2203
Value Proposition for MAT2203 ORAL ADMINISTRATION LACK OF NEPHROTOXICITY enables earlier release enables longer treatment duration from hospital or avoidance supported by oral of home infusion administration LIFE CYCLE MANAGEMENT Cryptococcal Meningitis (CM) (Proof of Concept) a= VALUE — ————_—_—__
Slide 13: EnACT: Cohort Results (Validation of Efficacy and Safety)
8 EnACT : Cohort 2 Results (Validation of Efficacy and Safety) EnACT Clinical Data VALIDATES the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity Exceeded the primary All patients completing No breakthrough Survival at Day 30, MAT2203 was safe and endpoint threshold induct
Slide 14: Cohort Key Secondary Efficacy Endpoint: Survival
“ Cohort 2 and Cohort 4 Key Secondary Efficacy Endpoint: Survival = MAT2203 Cohort 2s MAT2203 Cohort 4° = SoC 100) 98 95 95 a 95 93 «0 88 85 80 & 60 ae 4 20 Or Week 2 Week 4 Week 6 Week 10 Primary Endpoint Secondary Endpoint (Phase 3) (Phase 3) n/N= 39/40? 38/40 39/41 39/40? 37/40° 36/41 (38/40 36/4
Slide 15: MAT2203 Cohort Antifungal Activity
6 MAT2203 Cohort 4 Antifungal Activity Examples of Noteworthy Antifungal Activity in Patients with High Baseline Counts je) 2 | Treatment: Intervention Q | 2 | Treatment: Intervention ICC Result Result (} Ayal) 745,000 120,000 2,650 705 (} yal) 100,000 42,500 40 2 2 2 2 * * * VISIT DAY Screening Day
Slide 16: Phase III Aspergillus/IFI Study - Preliminary Design (Subject to FDA Agreement)
Phase III Aspergillus/IFI Study - Preliminary Design (Subject to FDA Agreement) + Toassess the efficacy, safety, and tolerability of MAT2203 in patients with Invasive Aspergillosis; Patients will be randomized 2:1 to receive either oral MAT2203 as “step down” treatment after initial treatment with I
Slide 17: MAT2203 Compassionate Use - Targeted Treatment of IFIs Throughout the Body
MAT2203 Compassionate Use - Targeted Treatment of IFls Throughout the Body Sinus Mucor nidicola Pansinusitis Lung Aspergillus calidoustus Pulmonary aspergillosis Skin Prototheca wickerhamii Skin infection Skin graft Fusarium species Wound infection Brain Cryptococcus Meningitis Brain [possible cocci
Slide 18: MAT2203 Compassionate Use Program
MAT2203 Compassionate Use Program Patient Description Patient #4 (37 v.o, female): + Systemic lupus erythematosus, chronic non-healing ulcer on left foot with underlying osteomyelitis caused by Rhodotorula mucilanginosa. Patient #2 (74.0. male): + Chronic immunosuppression, multiple painful skin les
Slide 19: MAT2203 Compassionate Use Program
MAT2203 Compassionate Use Program Patient Description Patient #4 (39 v.o. male) + Crohn's disease, s/p colon resection with ileostomy, retroperitoneal abscess. caused by azole-resistant Candida giabrata. Reason for initiating MAT2203 + Patient did not tolerate IV Ambisome Comments Discontinued MAT22
Slide 20: Beyond Small Molecules: Efficient and Safe Delivery of Nucleic Acids
Beyond Small Molecules: Efficient and Safe Delivery of Nucleic Acids Through LNCs and PS-NPs Internal Pipeline Focus (siRNAs and ASOs) and External Collaborations (mRNA) MATINAS ~~ BIOPHARMA
Slide 21: Unlocking the Full Potential of the LNC and PS-NP Platforms
a Unlocking the Full Potential of the LNC and PS-NP Platforms Matinas is working internally and with third parties to broaden its pipeline of LNC and PS-NP-based therapeutics FUTURE I UNDER EVALUATION Potential Therapeutic Applications INFECTION IMMUNE RX PROVEN © Anti-infectives » Vaccines » Antivi
Slide 22: PS-NP mRNA Formulations Remain Biologically Active for at Least 17 Weeks at 4°C
2 PS-NP mRNA Formulations Remain Biologically Active for at Least 17 Weeks at 4°C WEEK 0. WEEK 5. WEEK 10 WEEK 17 RNA2 17 Week 4° C Stability mWeekO mWeek5S mWeek 10 =Week 17 8 62ng mRNA | 18 hrs post incubation | HeLa cells z ¢ LNP mRNACOVID vaccine + Moderna: up to 30 days? 2 stability at 2-8° C *
Slide 23: Successful In Vivo Delivery of Firefly Luciferase mRNA with PS-NPs
Successful /n Vivo Delivery of Firefly Luciferase mRNA with PS-NPs 10°. Average radiance (IP Injection) In vivo imaging Average radiance (IM Injection) Ex vivo post-mortem imaging 407-4 6 Hours i Control PS-NP LUC mRNA 6hr 24hr 10° 48hr 72hr . + fH 10+ a € gs & 403. 10 102. Control PS-NP LUC mRNA 2
Slide 24: National Resilience Collaboration Focused on mRNA and Nucleic Acids
National Resilience Collaboration Focused on mRNA and Nucleic Acids [RESILIENCE Provide manufacturing capabilities in: Focused on creating the processes os Os and platforms that will allow xy scientists to make novel therapies quickly, safely, and at scale Gene therapy Nucleic acids Cell therapy Wor
Slide 25: Rapid Evolution of Platforms Sets Stage for Further Development
Rapid Evolution of Platforms Sets Stage for Further Development Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Precise control of LNC LNC uptake by LINC uptake by Particle size immune cells exvivo immune cells in vitro ‘Successful in-vitro 2 Logimproverent in delivery of mRNA in vitro efficacy Demo
Slide 26: Expanding LNC and PS-NP Intellectual Property Portfolio
28 Expanding LNC and PS-NP Intellectual Property Portfolio Continuingly increasing our patent suite to increase protection and exclusivity ao MAT2203 potentially entitled to 12+ years of exclusivity (QIDP & ODD status) Global Platform IP Recent patent base protection out to applications based on 203
Slide 27: Experienced Leadership Team
Experienced Leadership Team EXECUTIVE TEAM Jerome D. Jabbour, J.D. Chief Executive Officer Chief Business Officer S<MILLENDO. *sunovion @fReliant™ James Ferguson, M.D. Chief Medical Officer Ie, AMGEN sna Astrazeneca? Thomas Hoover, MBA Keith Kucinski, CPA, Chief Financial Officer PAR barr Chief Deve
Slide 28: Matinas Investment Thesis
2% Matinas Investment Thesis Financial Summary pe Runway into 2H 2024 th $24.9M" in Cash, Cash Equivalents and Marketable Securities 4s otoaa1/22 Ss Non-Dilutive Financing Options Ee vy [@ 2023 Milestones & Catalysts FDA Meeting and Feedback on MAT2203 Phase 3 IFI program @B =. Invitro data from Nat
Matinas BioPharma Holdings — Investor Presentation (May 2023) on 6ix